Skip to main content
Clinical Trials/NCT01638988
NCT01638988WithdrawnPhase 3

Clomifene Citrate Versus Metformin in First-line Treatment of Infertility in Patients With Polycystic Ovary Syndrome (PCOS) and a Resistance to Insulin. Randomised Controlled Study

Clinique Ovo1 site in 1 countryStarted: September 2013Last updated:
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Phase 3
Status
Withdrawn
Sponsor
Locations
1
Primary Endpoint
Biochemical pregnancy

Study Overview

Brief Summary

The results of studies conducted until now does not determine what the best way to treat infertility in the first line with patients with Polycystic ovary syndrome (PCOS). This study objective is to determine the best treatment for such patients. The long-term consequence health of women with PCOS are multiple. The woman with PCOS has a risk of developing metabolic diseases, heart diseases, diabetes Type II or anovulatory infertility. The insulin resistance plays an important role in all this medical condition. Clomiphene Citrate (CC) remains the first line treatment to induce ovulation in women with PCOS and anovulatory infertility.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to 35 Years (Adult)
Sex
Female
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Women aged from 18 to 35
  • Infertility for a period of a year or more or 6 month of irregular menstrual cycle
  • PCOS under the Rotterdam criteria
  • Insulin resistance HOMA-IR > 2.5
  • Normal semen analysis values
  • Normal values of the following blood analysis: FSH, LH, Estradiol, AMH, TSH, Prolactine, Fasting glucose level, hemoglobin A1C, AST, ALT, alkaline phosphatase, SHBG, 17OH progesterone, DHEAS, Androstenedione, total testosterone, LDL, HDL, total cholesterol, Triglycerides, oral glucose tolerance test

Exclusion Criteria

  • Tubular factor
  • Normal ovarian reserve
  • Prior use of CC or Metformin, hypoglycemic agents, glucocorticoids, anti-androgen, weight-loss agent or oral contraceptives in the past 6 months
  • Neoplasia
  • BMI > 35
  • Renal, hepatic or cardiac failure
  • Lactic, acidosis antecedent

Arms & Interventions

Metformin

Experimental

Intervention: Metformin (Drug)

Clomiphene Citrate

Active Comparator

Intervention: Clomiphene citrate (Drug)

Outcomes

Primary Outcomes

Biochemical pregnancy

Time Frame: 1 month

Rate of biochemical pregnancy

Secondary Outcomes

  • Ovulation rate(1 month)
  • BMI and waist size changing(6 months)
  • Live birth rate(6 months)
  • AMH correlation/variation in function of Metformin(6 months)
  • Spontaneous abortion rate(6 months)
  • Insulin resistance changing(6 months)

Investigators

Sponsor
Clinique Ovo
Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials